首页|补肝强肾壮骨方治疗肝肾亏虚型原发性骨质疏松症的临床研究

补肝强肾壮骨方治疗肝肾亏虚型原发性骨质疏松症的临床研究

Study on the treatment of primary osteoporosis of liver and kidney deficiency type with Bugan Qiangshen Zhuanggu Formula

扫码查看
目的 探讨使用补肝强肾壮骨方治疗肝肾亏虚型原发性骨质疏松症患者的临床效果.方法 纳入2020年4月-2023年10月天台县人民医收治的130例肝肾亏虚型原发性骨质疏松症患者,采用随机数表法分为对照组(65例)和观察组(65例).对照组予以阿仑膦酸钠片及碳酸钙D3片口服治疗,观察组患者在此基础上增加补肝强肾壮骨方治疗.比较2组患者中医证候疗效水平,检测治疗前后骨密度值及血清骨代谢指标变化,比较VAS评分和SF-36评分差异,观察药物不良反应.结果 观察组中医证候总有效率(93.85%,61/65)高于对照组(69.23%,45/65),差异有统计学意义(P<0.001).观察组治疗12周VAS评分[(2.47±0.63)分]低于对照组[(3.29±0.72)分,P<0.001],而 SF-36 评分[(85.73±6.49)分]高于对照组[(74.65±6.27)分,P<0.001].观察组治疗12周后腰椎L2~4、右股骨颈和左桡骨远端骨密度值均高于对照组(P<0.001).观察组治疗12周后血清骨特异性碱性磷酸酶(BALP)、Ⅰ型前胶原氨基端前肽(P1NP)均高于对照组,而血清Ⅰ型胶原交联C端肽(CTX)、Ⅰ型胶原交联氨基末端肽(NTX)均低于对照组(P<0.001).2组药物不良反应发生率比较差异无统计学意义(P>0.05).结论 在阿仑膦酸钠、碳酸钙D3基础上,增加补肝强肾壮骨方治疗肝肾亏虚型原发性骨质疏松症,可有效改善患者中医症候,缓解疼痛,提高生活质量,其作用机制可能与增强患者骨密度,调节骨骼代谢功能相关.
Objective To explore the clinical effect of Bugan Qiangshen Zhuanggu Formula in treating primary osteopo-rosis(liver and kidney deficiency type).Methods A total of 130 patients with primary osteoporosis(liver and kidney deficiency type)admitted to Tiantai County People's Hospital from April 2020 to October 2023 were studied,and were divided into control group(65 cases)and observation group(65 cases)randomly.The control group were given alendr-onate sodium tablets and calcium carbonate D3 tablets,while the observation group received additional treatment with Bugan Qiangshen Zhuanggu Formula.The therapeutic effect level of traditional Chinese medicine syndrome in patients were evaluated,the changes in bone density and serum bone metabolism indicators were detected,the differences in VAS score and SF-36 score were compared,and the adverse drug reactions were observed.Results The overall effective rate of traditional Chinese medicine syndromes in observation group(93.85%,61/65)was higher than control group(69.23%,45/65,P<0.001).After 12 weeks of treatment,the bone density values of the lumbar spine L2_4,right fem-oral neck,and left distal radius in the observation group were higher than the control group(P<0.001).The VAS score of observation group(2.47±0.63)was lower than control group(3.29±0.72,P<0.001),while the SF-36 score(85.73±6.49)was higher than control group(74.65±6.27,P<0.001).The levels of serum bone-specific alkaline phosphatase(BALP)and type Ⅰ procollagen amino terminal peptide(P1NP)in observation group was higher than con-trol group,but the levels of serum cross-linked type 1 collagen C-terminal peptide(CTX)and N-telopeptide of type Ⅰcollagen(NTX)were lower than control group(P<0.001).The incidence of adverse reactions between the two groups was no difference(P>0.05).Conclusion Bugan Qiangshen Zhuanggu Formula combined with alendronate sodium and calcium carbonate D3 can effectively improve traditional Chinese medicine symptoms,alleviate pain reactions,and im-prove quality of life in patients with primary osteoporosis of liver and kidney deficiency type.Its mechanism of action is closely related to enhancing patient bone density and regulating bone metabolism function.

Primary osteoporosisLiver and kidney deficiency typeBugan Qiangshen Zhuanggu FormulaAlendronate sodiumCalcium carbonate D3Clinical efficacy

杨军、范续

展开 >

天台县人民医院骨科,浙江台州 317200

原发性骨质疏松症 肝肾亏虚型 补肝强肾壮骨方 阿仑膦酸钠 碳酸钙D3 临床疗效

浙江省中医药科技计划项目

2023ZL201

2024

中华全科医学
中华预防医学会,安徽省全科医学会

中华全科医学

CSTPCD
影响因子:1.688
ISSN:1674-4152
年,卷(期):2024.22(7)